Display options
Cite
Chang HK, Kim PH, Cho HM, et al. Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis. Mol Ther. 2016;24(9):1644-54doi: 10.1038/mt.2016.120.
Chang, H. K., Kim, P. H., Cho, H. M., Yum, S. Y., Choi, Y. J., Son, Y., Lee, D., Kang, I., Kang, K. S., Jang, G., & Cho, J. Y. (2016). Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis. Molecular therapy : the journal of the American Society of Gene Therapy, 24(9), 1644-54. https://doi.org/10.1038/mt.2016.120
Chang, Hyun-Kyung, et al. "Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis." Molecular therapy : the journal of the American Society of Gene Therapy vol. 24,9 (2016): 1644-54. doi: https://doi.org/10.1038/mt.2016.120
Chang HK, Kim PH, Cho HM, Yum SY, Choi YJ, Son Y, Lee D, Kang I, Kang KS, Jang G, Cho JY. Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis. Mol Ther. 2016 Sep;24(9):1644-54. doi: 10.1038/mt.2016.120. Epub 2016 Jun 10. PMID: 27434585; PMCID: PMC5113099.
Copy Download .nbib Format: NLM
Share it on

Mol Ther. 2016 Sep;24(9):1644-54. doi: 10.1038/mt.2016.120. Epub 2016 Jun 10.

Inducible HGF-secreting Human Umbilical Cord Blood-derived MSCs Produced via TALEN-mediated Genome Editing Promoted Angiogenesis.

Molecular therapy : the journal of the American Society of Gene Therapy

Hyun-Kyung Chang, Pyung-Hwan Kim, Hyun-Min Cho, Soo-Young Yum, Young-Jin Choi, YeonSung Son, DaBin Lee, InSung Kang, Kyung-Sun Kang, Goo Jang, Je-Yoel Cho

Affiliations

  1. Department of Biochemistry, BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  2. Current address: Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Daejeon, South Korea.
  3. Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  4. Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.

PMID: 27434585 PMCID: PMC5113099 DOI: 10.1038/mt.2016.120

Abstract

Mesenchymal stem cells (MSCs) promote therapeutic angiogenesis to cure serious vascular disorders. However, their survival period and cytokine-secretory capacity are limited. Although hepatocyte growth factor (HGF) can accelerate the rate of angiogenesis, recombinant HGF is limited because of its very short half-life (<3-5 minutes). Thus, continuous treatment with HGF is required to obtain an effective therapeutic response. To overcome these limitations, we produced genome-edited MSCs that secreted HGF upon drug-specific induction. The inducible HGF expression cassette was integrated into a safe harbor site in an MSC chromosome using the TALEN system, resulting in the production of TetOn-HGF/human umbilical cord blood-derived (hUCB)-MSCs. Functional assessment of the TetOn-HGF/hUCB-MSCs showed that they had enhanced mobility upon the induction of HGF expression. Moreover, long-term exposure by doxycycline (Dox)-treated TetOn-HGF/hUCB-MSCs enhanced the anti-apoptotic responses of genome-edited MSCs subjected to oxidative stress and improved the tube-formation ability. Furthermore, TetOn-HGF/hUCB-MSCs encapsulated by arginine-glycine-aspartic acid (RGD)-alginate microgel induced to express HGF improved in vivo angiogenesis in a mouse hindlimb ischemia model. This study showed that the inducible HGF-expressing hUCB-MSCs are competent to continuously express and secrete HGF in a controlled manner. Thus, the MSCs that express HGF in an inducible manner are a useful therapeutic modality for the treatment of vascular diseases requiring angiogenesis.

References

  1. Gene Ther. 2000 Oct;7(19):1664-71 - PubMed
  2. Diabetes. 2001 Jun;50(6):1472-81 - PubMed
  3. Annu Rev Cell Dev Biol. 2003;19:1-22 - PubMed
  4. Oncologist. 2004;9 Suppl 1:2-10 - PubMed
  5. Cell Res. 2005 Jan;15(1):49-51 - PubMed
  6. Ann Thorac Surg. 2005 Jul;80(1):229-36; discussion 236-7 - PubMed
  7. J Immunol. 2005 Oct 1;175(7):4745-53 - PubMed
  8. Circ Res. 2005 Sep 30;97(7):615-7 - PubMed
  9. EMBO J. 1991 Oct;10(10):2867-78 - PubMed
  10. Science. 2007 Jun 8;316(5830):1422-3; author reply 1422-3 - PubMed
  11. Stem Cells. 2007 Oct;25(10):2648-59 - PubMed
  12. J Cell Physiol. 2007 Nov;213(2):341-7 - PubMed
  13. Science. 1991 Feb 15;251(4995):802-4 - PubMed
  14. Diabetes. 2008 Jul;57(7):1759-67 - PubMed
  15. Circ Res. 2008 Nov 21;103(11):1204-19 - PubMed
  16. Histol Histopathol. 2010 Jun;25(6):807-15 - PubMed
  17. Int Immunopharmacol. 2010 Dec;10(12):1496-500 - PubMed
  18. Nature. 2012 Nov 1;491(7422):114-8 - PubMed
  19. Cancer Sci. 2013 Apr;104(4):431-6 - PubMed
  20. Mol Cell Proteomics. 2014 Jan;13(1):30-48 - PubMed
  21. Acta Biomater. 2014 Jul;10(7):3007-17 - PubMed
  22. Stem Cells Transl Med. 2014 Jul;3(7):821-35 - PubMed
  23. J Control Release. 2014 Aug 10;187:1-13 - PubMed
  24. Clin Sci (Lond). 2015 Dec;129(12):1173-93 - PubMed
  25. Biomedicines. 2014 Oct 21;2(4):247-262 - PubMed
  26. Biomedicines. 2014 Oct 31;2(4):275-300 - PubMed
  27. Cell. 1994 Apr 22;77(2):261-71 - PubMed
  28. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4357-61 - PubMed
  29. Diabetes. 1997 Jan;46(1):138-42 - PubMed
  30. J Hypertens. 1996 Sep;14(9):1067-72 - PubMed
  31. J Lab Clin Med. 1997 Nov;130(5):530-4 - PubMed
  32. Kidney Int. 1998 Oct;54(4):1392-3 - PubMed

Publication Types